The oncogenic versus suppressor roles of mitochondrial genes has been long debated. Peculiar features of mitochondrial genetics such as hetero/homoplasmy and mutation threshold are seldom taken into account in this debate. Mitochondrial DNA (mtDNA) mutations generally have been claimed to be pro-tumorigenic, but they are also hallmarks of mostly benign oncocytic tumors where they help reduce adaptation to hypoxia by destabilizing hypoxia-inducible factor-1α (HIF1α).
Introduction
Genes encoded by mitochondrial DNA (mtDNA) have long been suspected to be actively involved in tumorigenesis, when cells require high amounts of energy to grow and proliferate under few constraints. Although the association between somatic mtDNA mutations and cancer has been widely demonstrated, the mechanistic role played by these mutations is far from being elucidated.
The most credited hypothesis is that they may foster tumor progression in various ways such as through effects on regulation of apoptosis, hypoxia-inducible factor-1α (HIF1α) stabilization, reactive oxygen species (ROS) production and hence metastatic potential (1) (2) (3) (4) . A question still open in cancer biology concerns the oncogenic versus the oncosuppressor behavior of metabolic genes (5, 6) , which incorporate both nuclear-and mtDNA-encoded respiratory complex subunits.
Enzymes such as succinate dehydrogenase (SDH) and fumarate hydratase (FH) are actively involved in tumorigenesis, through imbalance of the tricarboxylic acids (TCA) cycle and stabilization of HIF1α (7, 8) . Similarly, respiratory complex I (CI) genes may be crucial in regulating cancer cell metabolism, since their function directly impinges on TCA. Alteration of oxidative metabolism resulting from mtDNA mutations may sustain, along with other causes, the triggering of the "Warburg effect" that characterizes cancer cells and permits a shift towards glycolysis, hence aiding tumor progression (9, 10) . In this context, changes in the metabolic status of cancer cells are closely related to the degree of respiratory chain dysfunction, which in turn depends on both mtDNA mutation type (hampering function and/or assembly of complexes) and mutation load.
Reports that describe association of non-neutral mtDNA mutations with all types of cancers do not dwell on the peculiar features of mitochondrial genetics, namely the concept of homo-versus heteroplasmy, i.e. the coexistence of different mtDNA genotypes. Evaluation of the effects of mtDNA mutations must take into account the existence of a threshold above which a pathologic phenotype becomes evident, due to the physiological polyploidy of the mitochondrial chromosome, which has all too rarely been considered when dissecting the mechanisms underlying the metabolic
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Author Manuscript Published OnlineFirst on August 18, 2011; DOI: 10.1158/0008-5472. CAN-11-1042 adaptation of cancer (3) . In the vast majority of cases, clearly damaging mtDNA mutations described in tumors are reported as homoplasmic, suggesting that they may determine a pathologic phenotype despite an apparent positive selection (11) (12) (13) (14) (15) (16) (17) (18) (19) .
A specific subset of tumors, namely oncocytic neoplasias, harbor high loads of damaging mtDNA mutations and yet retain, in most cases, a benign, low-proliferating, non-invasive behaviour (12) (13) (14) (20) (21) (22) (23) . A strong association between CI disruption and HIF1α destabilization has been demonstrated through increase of α-ketoglutarate (α-KG)/succinate (SA) ratio, which may be responsible for a higher affinity/activity of the prolyl-hydroxylase (PHD) that mediates HIF1α proteasomal-degradation. Such metabolic switch was suggested to explain why oncocytic tumors may escape malignancy (23) . Thus, certain mtDNA mutations may indeed contribute to reduce tumor growth, depending on their effect on respiratory complexes assembly and their heteroplasmy threshold, which, to the best of our knowledge, has never been defined so far.
Here we demonstrate that high loads of a disruptive CI mutation frequently associated to human tumors (11, 12, 14, 15) hamper tumorigenic potential in vitro and in vivo. Threshold level for antitumorigenic effect of a mtDNA mutation in cancer, leading to oncocytic transformation, was determined, allowing us to define a novel type of tumor-implicated gene, namely the double-edged oncojanus.
Materials and methods

Cell cultures and growth conditions
Human thyroid carcinoma cell line XTC1 was derived from an oncocytic thyroid tumor (24) . ZTC1 cells were a heteroplasmic clone obtained by serial dilution of XTC1 (22) . Cybrids HXTC1 and HZTC1 were generated from human osteosarcoma 143B.TK cells and previously characterized (23) . They will be renamed here as OS-93 and OS-85, respectively, the numbers indicating the percentage of MTND1 mutation load. A parental control cybrid (CC), previously characterized (23) 93 and OS-85 was also used. OSC-83 and OSC-78 were derived from xenografts after in vivo injection of OS-85 cells. Cybrid cell lines were grown in DMEM, as previously described (23) .
All cell lines were authenticated by mtDNA genotyping. Occurrence of the m.3571insC mutation and accurate quantification of heteroplasmy levels as previously described (25) , was verified before and after explant as well as before each in vitro experiment. To the best of our knowledge no other cell line is known to harbor such mutation. Moreover, to authenticate cybrid cell lines, the occurrence of the known TP53 mutation g.13055G>C harbored by the parental 143B.TK cells was verified (Supp. Fig.5 ). Coexistence of the TP53 mutation along with the m.3571insC unequivocally identified cybrids, whereas thyroid cell lines harbored exclusively the m.3571insC mutation.
Cell viability measurement
Cells (4x10 4 ) were incubated in glucose-free DMEM supplemented with 5mmol/L galactose, 5mmol/L Na-pyruvate and 10% FBS (DMEM-galactose). Viability was determined using the colorimetric sulforhodamine B assay (26) .
Complex I activity and ATP synthesis
CI assembly and in-gel activity were determined after Blue-Native electrophoresis of isolated mitochondria, as previously described (27) . The rate of mitochondrial ATP synthesis driven by CI and CII was performed in aliquots of digitonin-permeabilized cells and normalized on citrate synthase activity as previously described (28) . Briefly, aliquots of cells (0.1-0.2 mg protein) were incubated with 5 mM malate plus 5 mM pyruvate (CI substrates) or with 10 mM succinate (CII substrate) plus 2 μg/ml rotenone. The reaction was started by addition of 0.2 mM ADP in the presence of luciferine/luciferase, and chemiluminescence was evaluated as a function of time with a luminometer. After addition of 10 μM oligomycin, the chemiluminescence signal was calibrated with an internal ATP standard.
Soft agar assay
Research. were then counted using a dissecting microscope.
Immunohistochemistry
Immunohistochemical staining (IHC) with antibodies against MTND6 CI subunit (Invitrogen, Milan, Italy) and HIF1α (Upstate Biotech, Billerica, MA, USA) was performed, as previously reported (13) .
α-ketoglutarate and succinate measurements
Cells were incubated in DMEM with and without glutamine for 24h. Measurements of metabolites α-KG and SA were performed essentially as previously described (23) .
Research. Extractions from two distant tumor areas were performed for large xenografts to account form tissue heterogeneity.
MtDNA sequencing
Whole mtDNA resequencing was performed with MitoAll (Applied Biosystems, Foster City, CA, USA) as previously described (14) in order to verify that xenografts had not accumulated mutations apart from the m.3571insC.
Heteroplasmy evaluation
Mutant load for m.3571insC was determined using F-PCR according to previously optimized protocols for mutations in difficult sequence contexts such as in homopolymers (25) . To ensure specificity of the mutant load evaluation, each analysis was performed in quadruplicate and all samples were run in the same reaction plate.
Electron microscopy (EM) and morphometric analysis
Author Manuscript Published OnlineFirst on August 18, 2011; DOI: 10.1158/0008-5472. CAN-11-1042 Xenograft biopsies were immediately collected and processed (14) . Sections (1μm) were stained with 1% toluidine blue for morphology control and EM area selection. Thin sections were observed with JEM-1011 Transmission Electron Microscope (Jeol, Ltd). For each group three xenografts were analyzed, observing at least two different areas of each tumor to rule out intratumor heterogeneity. For morphometric analysis, 95 mitochondria per sample were measured on electron micrographs (magnification 15000X), and statistically analyzed using Olympus iTEM Imaging software.
Pimonidazole staining
Animals were injected intraperitoneally with 60mg/kg pimonidazole (Hypoxyprobe-1 Plus Kit, HPI, Burlington, MA) 3h prior to sacrifice. Xenografts were snap-frozen and cut in 10μm slices.
Tissues were fixed for 20min with cold acetone, kept for 1h with PBS containing 5% FBS and incubated for 1h with FITC-MAb1 antibody (1:10). Fluorescence was visualized with a digital imaging system using an inverted epifluorescence microscope with 63X/1.4 oil objective (Nikon Eclipse Ti-U, Nikon, Japan) at 488nm. Images were captured with a back-illuminated Photometrics Cascade CCD camera system (Roper Scientific, Tucson, AZ, USA) and elaborated with Metamorph acquisition/analysis software (Universal Imaging Corp., Downingtown, PA, USA). SigmaStat 3.5 software was used for statistical analysis applying Student's t-test unless otherwise indicated.
RNA extraction and Real Time PCR analysis
Results
High loads of the m.3571insC MTND1 mutation hamper tumor growth
We have previously generated and fully characterized a unique panel of human tumor cell lines harboring the m.3571insC mutation in MTND1 gene of CI, using two different tumor nuclear backgrounds and selecting different levels of heteroplasmy (23 from the m.3571insC were detected in xenografts upon re-sequencing the whole mtDNA.
Interestingly, the presence of high loads of mutant mtDNA strongly hampered the growth of the highly aggressive osteosarcoma. On the other hand, the least aggressive was the nearly homoplasmic mutant XTC1 cell line, which failed to grow in any injected animal (Fig.1C) . Most importantly, high loads of a disruptive CI mutation were sufficient to reduce the tumorigenic potential of at least two different types of cancer, osteosarcoma and thyroid carcinoma, regardless of their intrinsic aggressive behavior.
HIF1α destabilization, not apoptosis, contributes to tumor growth reduction
We investigated the possible causes for the observed decrease in tumorigenic potential induced by the high m.3571insC mutation load. Apoptosis has been previously described to be differentially activated in homoplasmic versus heteroplasmic cells (3), yet typical apoptotic DNA laddering and nuclear chromatin condensation were observed exclusively in OS-85-derived tumors, regardless of their hosting mouse strain ( Fig.2A and B) , ruling out the role of apoptosis in the reduction of tumorigenic potential. On the basis of the occurrence of a chronic pseudo-normoxic condition in tumors bearing homoplasmic disruptive mtDNA mutations (23), we decided to investigate whether HIF1α destabilization was also induced in xenografts. Immunohistochemical (IHC) staining of CI MTND6 subunit was negative in OS-93-derived tumors but positive in most OS-85-derived masses.
Correspondingly, HIF1α staining was negative wherever CI suffered from at least partial disassembly ( Fig.2C) (23) . Xenografts derived from OS-85 cells showed heterogeneous tumor volumes. Staining with hypoxic marker pimonidazole (30) revealed that small tumor masses displayed greater hypoxic areas compared to large ones, indicating that HIF1α stabilization was prevented in CI-deficient tumors despite the low-oxygen tension microenvironment in vivo (Fig.2D) . Moreover, a significantly lower expression of HIF1α-responding genes, namely glucose transporter-1 (GLUT1), vascular endothelial growth factor A (VEGFA) and lactate dehydrogenase 
A (LDHA), was observed in OS-93 xenografts (Fig.2E) , suggesting that HIF1α destabilization had functional consequences on downstream gene expression.
A mutation threshold must be reached to trigger tumor growth inhibition
After detailed analysis of the individual growth curves of heteroplasmic-derived OS-85 osteosarcoma xenografts, we observed that only a few masses were markedly smaller than the majority (Fig.3A) , which prompted us to quantify precisely the MTND1 mutation load in all developed tumors. A representative experiment is reported in figure 3B . Plotting heteroplasmy levels against nude mice tumor volumes indicated that only smaller OS-85-derived tumors maintained unaltered the original cell mutation load. On the contrary, all larger tumors underwent a shift toward the wild-type allele (Fig.3C) , suggesting a purifying selection mechanism in order to overcome the damaging effect of mutations on tumor growth. A threshold for the m.3571insC mutation was hence defined between 81 and 83%, above which mitochondrial energetic impairment may not be sustained by cancer cells. In fact, tumor masses in which the genotype had partly reverted to wild-type below 81% presented CI subunit staining (Fig.2C) . A load >83% was therefore sufficient to induce the same phenotype as a load close to homoplasmy, similar to that of OS-93-derived masses. A lower HIF1α protein expression level was observed in smaller OS-85-derived masses above threshold, confirming IHC data (Fig.3D ) and the functional consequences on HIF1α-responding genes expression were comparable to those observed in Rag2 -/-;γc -/-(Supp. Fig.2 ). Interestingly, no tumor was observed to shift towards the mutant allele, suggesting that random drift may not be the mechanism determining a change in tumor genotype during progression, when non-neutral mutations are involved.
Tumor growth reduction is closely linked to threshold-determined energetic impairment
To assess the functional effects of the mutation threshold on cell phenotype and tumor growth, the smallest and largest tumors were utilized for further analyses, respectively bearing 83% (OST-83,
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above threshold) and 78% (OST-78, below threshold) mutation load, originating from the very same culture batch of OS-85. Cell cultures were generated from xenografts (Fig.3A) and OSC-83 and OSC-78 cells were obtained (82.8%±1.5 and 78.3%±1.3 mutation load, respectively, Fig.3B) carrying identical heteroplasmy levels to those measured in xenografts. Viability of OSC-78 cells after 48h of incubation in galactose medium was significantly higher compared to OSC-83 and to the original OS-85 cells (Fig.4A) . Therefore, only cells bearing a mutation load below the threshold were able to grow when forced to use oxidative phosphorylation solely for energy production. CI assembly and activity were markedly reduced in OSC-83, whereas no difference in complex IIdriven ATP synthesis was observed, suggesting no alteration of the remaining oxidative phosphorylation (Fig.4B) . Further, the α-KG/SA ratio was significantly higher in OSC-83 compared to OSC-78 both in presence and absence of glutamine (Fig.4C) , demonstrating that CI disruption influenced the balance of these TCA cycle metabolites and that α-KG production in OSC-83 cells was glutaminolysis-independent. Instead of a variation of α-KG levels, such an increase was due to a relevant decrease in succinate (Supp. Table 1 ). Concordantly, stabilized HIF1α was detected exclusively in OSC-78 (Fig.4D) . When OSC-78 and OSC-83 cells were reinjected in nude mice, OSC-78-derived tumors grew significantly larger than the high-load mutant OSC-83-derived tumors (Fig.5A ), in agreement with the heteroplasmy threshold we have defined (Fig.5B) . Finally, the contribution of ROS overproduction on HIF1α stabilization was ruled out in all clones analyzed. In fact, we failed to observe any significant difference in hydrogen peroxide and anion superoxide levels irrespective of the mutation load (Supp. Fig.3A and 3B ).
High loads of m.3571insC trigger oncocytic transformation
The m.3571insC mutation is a hallmark of oncocytic tumors together with similar truncating mutations mainly occurring in homoplasmy (11-15, 21, 23, 31) . In order to verify whether this mutation, when present above threshold, was sufficient to trigger oncocytic transformation, we examined xenografts by electron microscopy. We observed a mitochondria-rich phenotype only in specimens above threshold level (Fig.6A) . A striking resemblance to oncocytic tumors was evident in terms of mitochondrial number and swollen deranged organelle morphology, despite the nonepithelial origin of the osteosarcoma xenografts (Fig.6A, a and The hypothesis that the same threshold of disruptive mtDNA mutations we have here defined accompanies oncocytic change in patients was supported by a re-analysis of over 100 cases from thyroid, pituitary and salivary gland, kidney and breast oncocytic neoplasms (12-14, 22, 23) . In these tumors the heteroplasmy of the mtDNA mutations was evaluated. Most of the latter were found to affect CI assembly and presented a mutant load greater than 81%, confirming that this was the threshold needed to acquire an oncocytic phenotype (Supp. Fig.4 ).
Discussion
We have shown here that homoplasmy of a truncating mutation in MTND1 hampers the tumorigenic and metastatic potential of cancer cells in vivo. For the first time a precise threshold for such mutation, sufficient to increase α-KG/SA ratio, induce HIF1α destabilization and ultimately trigger growth arrest, has been identified.
Our proof for the principle regarding the anti-tumorigenic effect of mtDNA truncating mutations was obtained using a unique cell model (23) , experimentally reinforced through re-injection of highly isogenic clones OSC-78 and -83, carrying a mutation load below and above threshold, respectively. In agreement with previous observations in patients (23) , tumor xenografts bearing a mutation above threshold displayed pseudo-normoxia, showing HIF1α destabilization despite being
Research. truly hypoxic. HIF1α is considered to be one of the master regulators of the metabolic adaptation needed by cancer cells to progress to malignancy (7, 8, 32) . Therefore this mechanism, tightly linked to the α-KG/SA imbalance as we have demonstrated, may be sufficient to drive the tumor into a 'blind alley' due to both respiratory impairment and lack of HIF1α-dependent glycolysis induction (22) . Accumulation of NADH and inhibition of α-ketoglutarate dehydrogenase, rather than activation of glutaminolysis (10) here investigated, which may not be a ROS-generating mutation, if one considers that the main ROS production site might be lacking as a whole (23, (34) (35) (36) . Moreover, the mutant load ought to be considered when analyzing functional effects of mtDNA mutations. The threshold model we propose here implies that, below threshold, CI is present and functioning correctly, in contrast to the case of a missense mutation leading to the coexistence of non-mutant along with mutant, ROSproducing CI.
The most important consideration comes from the strong association between homoplasmic disassembling mtDNA mutations and a mostly benign oncocytic tumor phenotype. Our studies in mice have shown that, upon trespassing the threshold, the mutation is sufficient to trigger oncocytic transformation, even in a non-epithelial cancer (Fig.6A) . We have provided evidence that a single mtDNA mutation is able to generate a specific tumor phenotype, strengthening our hypothesis that mtDNA mutations represent a secondary hit in cancer progression which may determine the oncocytic phenotype subsequently to primary oncogenic transformation (14, 21, 22) . Patients with oncocytic tumors rarely present with highly aggressive, metastatic cancers. In the vast majority of cases, these tumors are surgically removed because of hindrance at the site of occurrence, such as in the case of oncocytic pituitary adenoma. In salivary glands, oncocytoma and Warthin tumors are considered benign and even, in some cases, non-neoplastic entities, similarly to oncocytic cells in Hashimoto's thyroiditis (37) . Kidney oncocytoma is usually considered benign and is only rarely metastatic. Interestingly, the main criterion used to distinguish renal oncocytoma from carcinoma during ultrasound scanning is absence of vascularization. Our findings provide an explanation for this clinical observation through HIF1α destabilization and, in turn, lack of VEGF pathway activation. In thyroid, criteria for malignancy are independent of oncocytic transformation (37) . In our long-standing experience on studying mtDNA sequence variation in all types of oncocytic tumors, the rare metastatic cancers encountered within the large sample set analyzed (over 150), were those not harboring mtDNA mutations. Therefore, mtDNA-determined oncocytic transformation appears to be functionally linked to a low tumorigenic and metastatic potential, which highlights the importance of homoplasmy of mtDNA mutations as prognostic markers.
Although warranting further investigation, our expression data on HIF1α-responding genes clearly point to a down-modulation of some of the HIF1α pathways as a strong candidate to re-direct the tumor fate, through the down-regulation of neovascularization and glycolytic metabolism. Induction of oncocytic transformation may therefore be envisioned as an approach to reduce tumor growth and abolish aggressive and metastatic potential.
Clinical applications may well arise from the translation of a genetic into a metabolic shift of the α-KG/SA ratio towards α-KG, which supports the use of cell-permeable α-KG derivatives in anticancer therapy (38) . Other strategies may impinge on CI disassembly in patients not harboring mtDNA mutations, degradation of assembly factors or even modulation of mitochondrial biogenesis to induce both the mutation and its accumulation. In fact, the phenomenon of homoplasmic shift 
leading to a low-proliferating tumor deserves to be thoroughly understood to be exploited in pathology. In this context, a careful evaluation of the biogenesis and mitophagy pathways leading to mtDNA turnover will likely provide the mechanistic insights underlying the accumulation of nonneutral mtDNA mutations observed in patients.
The findings that tumors grew in mice only when a reversion towards wild-type occurred prompts a revision of the "Warburg effect". It appeared that tumors were somehow forced to recover respiration to produce energy and, as our principle showed, stabilize HIF1α. Therefore, certain tumor stages appear to be respiration-dependent, most likely until more cell constraints have been removed and neovascularization has commenced together with nutrient influx to sustain a glycolytic shift. A model of waves of gene expression regulation to recover mitochondrial respiration during tumor progression has been recently proposed (10) . According to such model, mitochondria revitalization is a necessary process in the transition from a highly glycolytic to a partial/enhanced oxidative phosphorylation cancer bioenergetic phenotype. Respiration recovery may well not occur in presence of a homoplasmic mtDNA truncating mutation, strengthening the anti-tumorigenic effect of CI disassembly.
Interestingly, the threshold we report here for the m.3571insC is analogous to what has been described in MERRF syndrome (Myoclonic Epilepsy and Ragged-Red Fibers). In patients with this mitochondrial disease, in fact, the threshold value for the causative m.8344A>G mutation has been described to be 80% (39) , which further strengthens the hypothesis that 4/5 of mutant mitochondrial genomes in a cell may be sufficient to determine respiratory impairment.
In conclusion, our findings reveal a double-edged functional role for mitochondrial genes, closely correlated to a threshold effect. This property of such genes has allowed us to propose here the definition of oncojanus, indicating that, when mutated above a certain load, they determine an energetic impairment that prevents tumor growth.
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